

Edgar Filing: ATHEROGENICS INC - Form SC 13G/A

ATHEROGENICS INC  
Form SC 13G/A  
August 09, 2007

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G  
Under the Securities Exchange Act of 1934  
(Amendment No. 3)\*

Atherogenics Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

004225108

(CUSIP Number)

07/31/2007

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on subject class of securities, and for any subsequent amendment containing information which would prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section or all other provisions of the Act (however, see the Notes).

-----  
CUSIP No. 004225108  
-----  
-----

1. Names of Reporting Persons

Edgar Filing: ATHEROGENICS INC - Form SC 13G/A

IRS Identification No:

OppenheimerFunds, Inc.  
13-2527171

2. Check the Appropriate Box if a Member of a Group (See Instructions): Join

3. SEC Use Only

4. Citizenship or Place of Organization:  
Colorado

Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person With

5. Sole Voting Power:  
0

6. Shared Voting Power:  
0

7. Sole Dispositive Power:  
0

8. Shared Dispositive Power:  
0

9. Aggregate Amount Beneficially Owned by Each Reporting Person:  
0 (beneficial ownership disclaimed pursuant to Rule 13d-4 of the Exchange

10. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Ins  
[ ]

11. Percent of Class Represented by Amount in Row (11):  
0%

12. Type of Reporting Person (See Instructions):  
IA

Edgar Filing: ATHEROGENICS INC - Form SC 13G/A

-----  
Item:  
-----

-----  
1 (a) Name of Issuer:  
Atherogenics Inc.  
-----

-----  
1 (b) Address of Issuer's Principal Executive Offices:  
8995 Westside Parkway  
Alpharetta, GA 30004  
-----

-----  
2 (a) Name of Person Filing:  
OppenheimerFunds, Inc.  
-----

-----  
2 (b) Address of Principal Business Office or, if none, Residence:  
Two World Financial Center  
225 Liberty Street  
New York, NY 10281  
-----

-----  
2 (c) Citizenship:  
Colorado  
-----

-----  
2 (d) Title of Class of Securities:  
Common Stock  
-----

-----  
2 (e) CUSIP Number:  
004225108  
-----

-----  
3 OppenheimerFunds, Inc. is an investment adviser in accordance with Rule 13  
-----  
-----

Edgar Filing: ATHEROGENICS INC - Form SC 13G/A

4 (a) Amount beneficially owned:  
0 (beneficial ownership disclaimed pursuant to Rule 13d-4 of the Exchange  
-----  
-----

4 (b) Percent of class:  
0%  
-----  
-----

4 (c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:  
0

(ii) Shared power to vote or to direct the vote:  
0

(iii) Sole power to dispose or to direct the disposition of:  
0

(iv) Shared power to dispose or to direct the disposition of:  
0  
-----  
-----

5. Ownership of Five Percent or Less of a Class: [ X ]  
-----  
-----

6. Ownership of More than Five Percent on Behalf of Another Person.:  
N/A  
-----  
-----

7. Identification and Classification of the Subsidiary Which Acquired the Securities on Behalf of the Parent Holding Company:  
N/A  
-----  
-----

8. Identification and Classification of Members of the Group:  
N/A  
-----  
-----

9. Notice of Dissolution of Group:  
N/A  
-----  
-----

10. Certification:  
By signing below I certify that, to the best of my knowledge and belief, the securities listed above were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the price of the securities and were not acquired and are not held in connection with or as part of a transaction having that purpose or effect.  
-----  
-----

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information furnished is true, complete and correct.

08/08/200

Edgar Filing: ATHEROGENICS INC - Form SC 13G/A

Date

/s/ Mark S. Vandehey  
Signature

Mark S. Vandehey, Sr. Vice President  
and Chief Compliance Officer  
Name/Title

atherogenics a3 13g(053107).rtf